Biomea Fusion, Inc. (BMEA)

Market Cap	96.86M
Revenue (ttm)	n/a
Net Income (ttm)	-95.71M
Shares Out	70.70M
EPS (ttm)	-2.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,171,186
Open	1.270
Previous Close	1.300
Day's Range	1.240 - 1.380
52-Week Range	1.221 - 8.990
Beta	-0.18
Analysts	Strong Buy
Price Target	8.86 (+546.72%)
Earnings Date	Nov 4, 2025

About BMEA

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral covalent small molecule drugs to treat patients with metabolic diseases in the United States. It’s lead product candidate icovamenib, an orally bioavailable, potent, and covalent inhibitor of menin, a ubiquitously expressed scaffold protein that functions in histone modification and epigenetic gene regulation to impact multiple cellular processes including cell cycle control, apoptosis, and DNA damage repair. Biomea Fus...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 16, 2021
• Employees: 106
• Stock Exchange: NASDAQ
• Ticker Symbol: BMEA
• Website: https://biomeafusion.com

Analyst Summary

According to 7 analysts, the average rating for BMEA stock is "Strong Buy." The 12-month stock price target is $8.86, which is an increase of 546.72% from the latest price.

Price Target

$8.86

(546.72% upside)

Analyst Consensus: Strong Buy